Cargando…

Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema

PURPOSE: To investigate whether eyes with diabetic macular edema (DME) and central retinal thickness (CRT) >400 μm had better visual and anatomical outcomes compared to eyes with a CRT <400 μm when treated with intravitreal bevacizumab in a real-world setting. PATIENTS AND METHODS: Patients un...

Descripción completa

Detalles Bibliográficos
Autores principales: Mushtaq, Bushra, Crosby, Niall J, Dimopoulos, Antonios T, Lip, Peck Lin, Stavrou, Panagiota, El-Sherbiny, Samer, Yang, Yit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010623/
https://www.ncbi.nlm.nih.gov/pubmed/24812486
http://dx.doi.org/10.2147/OPTH.S56624
_version_ 1782479883920736256
author Mushtaq, Bushra
Crosby, Niall J
Dimopoulos, Antonios T
Lip, Peck Lin
Stavrou, Panagiota
El-Sherbiny, Samer
Yang, Yit
author_facet Mushtaq, Bushra
Crosby, Niall J
Dimopoulos, Antonios T
Lip, Peck Lin
Stavrou, Panagiota
El-Sherbiny, Samer
Yang, Yit
author_sort Mushtaq, Bushra
collection PubMed
description PURPOSE: To investigate whether eyes with diabetic macular edema (DME) and central retinal thickness (CRT) >400 μm had better visual and anatomical outcomes compared to eyes with a CRT <400 μm when treated with intravitreal bevacizumab in a real-world setting. PATIENTS AND METHODS: Patients undergoing intravitreal bevacizumab therapy for DME were identified from the departmental database of a tertiary referral unit. Following the initial injection, a retreatment was performed for any persistent macular edema, unless there had been no previous response to repeated doses. Recorded parameters included visual acuity, CRT on optical coherence tomography (spectral domain optical coherence tomography [SD-OCT]), and SD-OCT characteristics. Comparisons were made between data at baseline and 12 months after the first injection, and differences were tested for statistical significance using the Student’s t-test. RESULTS: In all, 175 eyes of 142 patients were analyzed. Patients in group 2 (CRT >400 μm) had significantly more injections than group 1 (CRT <400 μm) (4.0 versus 3.3; P=0.003). Both groups had similar numbers of eyes with preexisting epiretinal membrane and/or vitreomacular traction at baseline. The reduction in CRT was significantly greater in group 2 when compared to group 1 (P<0.0001). In terms of visual gain between baseline and month 12, each gained significantly by a mean of 0.12 logarithm of the minimum angle of resolution units (P=0.0001), but there was no difference between groups 1 and 2 (P=0.99). CONCLUSION: These results do not support a 400 μm baseline CRT cut-off for treating DME with bevacizumab, in contrast to published data on ranibizumab. Our results also indicate that patients with a thicker CRT require more bevacizumab injections, making treatment less cost-effective for these patients. Our results could be used by practitioners to support the use of bevacizumab in DME without applying a CRT cut-off.
format Online
Article
Text
id pubmed-4010623
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40106232014-05-08 Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema Mushtaq, Bushra Crosby, Niall J Dimopoulos, Antonios T Lip, Peck Lin Stavrou, Panagiota El-Sherbiny, Samer Yang, Yit Clin Ophthalmol Original Research PURPOSE: To investigate whether eyes with diabetic macular edema (DME) and central retinal thickness (CRT) >400 μm had better visual and anatomical outcomes compared to eyes with a CRT <400 μm when treated with intravitreal bevacizumab in a real-world setting. PATIENTS AND METHODS: Patients undergoing intravitreal bevacizumab therapy for DME were identified from the departmental database of a tertiary referral unit. Following the initial injection, a retreatment was performed for any persistent macular edema, unless there had been no previous response to repeated doses. Recorded parameters included visual acuity, CRT on optical coherence tomography (spectral domain optical coherence tomography [SD-OCT]), and SD-OCT characteristics. Comparisons were made between data at baseline and 12 months after the first injection, and differences were tested for statistical significance using the Student’s t-test. RESULTS: In all, 175 eyes of 142 patients were analyzed. Patients in group 2 (CRT >400 μm) had significantly more injections than group 1 (CRT <400 μm) (4.0 versus 3.3; P=0.003). Both groups had similar numbers of eyes with preexisting epiretinal membrane and/or vitreomacular traction at baseline. The reduction in CRT was significantly greater in group 2 when compared to group 1 (P<0.0001). In terms of visual gain between baseline and month 12, each gained significantly by a mean of 0.12 logarithm of the minimum angle of resolution units (P=0.0001), but there was no difference between groups 1 and 2 (P=0.99). CONCLUSION: These results do not support a 400 μm baseline CRT cut-off for treating DME with bevacizumab, in contrast to published data on ranibizumab. Our results also indicate that patients with a thicker CRT require more bevacizumab injections, making treatment less cost-effective for these patients. Our results could be used by practitioners to support the use of bevacizumab in DME without applying a CRT cut-off. Dove Medical Press 2014-04-28 /pmc/articles/PMC4010623/ /pubmed/24812486 http://dx.doi.org/10.2147/OPTH.S56624 Text en © 2014 Mushtaq et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Mushtaq, Bushra
Crosby, Niall J
Dimopoulos, Antonios T
Lip, Peck Lin
Stavrou, Panagiota
El-Sherbiny, Samer
Yang, Yit
Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema
title Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema
title_full Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema
title_fullStr Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema
title_full_unstemmed Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema
title_short Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema
title_sort effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010623/
https://www.ncbi.nlm.nih.gov/pubmed/24812486
http://dx.doi.org/10.2147/OPTH.S56624
work_keys_str_mv AT mushtaqbushra effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema
AT crosbyniallj effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema
AT dimopoulosantoniost effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema
AT lippecklin effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema
AT stavroupanagiota effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema
AT elsherbinysamer effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema
AT yangyit effectofinitialretinalthicknessonoutcomeofintravitrealbevacizumabtherapyfordiabeticmacularedema